Recently we published some materials about the modern process of creating new pharmaceutical agents (PAs), which first-year master’s student in biotechnology Oleksandr Zholobko shared during practical classes in the course “Modern Pharmaceutical Technologies.” The information presented by Oleksandr turned out to be so comprehensive and interesting that we decided to continue a series of such scientific-popular posts on our website.
Thus, the next trend in accelerating the development of new PAs is the transition to a new type of testing (in silico). It should be noted that this is a modern concept. In silico is a term that denotes computer modeling (simulation) of an experiment, often biological.
The phrase was created by analogy with the phrases in vivo (in a living organism) and in vitro (in a test tube), which are often used in biology, and is not Latin itself. The term in its spelling is close to the Latin expression in silicio – “in silicon,” since silicon, as a semiconductor material, plays an important role in the production of computer equipment (“chips”).
Given the development of such technologies, in the future it will be possible to forget about conventional in vivo and in vitro experiments. With the growing popularity of quantum computers, in silico experiments will emerge, which will be conducted through computer modeling. By conducting drug testing through computer modeling of organ functions, this technology can completely bypass clinical in vivo testing. In addition to the obvious savings in time and money, in silico testing will allow to practically completely eliminate animal experiments and side effects that may appear in humans during clinical trials.
We should understand that in its current form, these technologies and understanding of biology simply have not yet been created for modeling clinical trials at 100%, but significant progress has already been made in this field, namely: the creation of “organs-on-a-chip,” which are similar to those that researchers at the Wyss Institute have been working on for many years, and HumMod, created as “the most complete mathematical model of human physiology ever created,” which has already participated in several research projects.
The Virtual Physiological Human (VPH) institute has also created digital computer models that are already being used to study heart diseases and osteoporosis.
Examples of popularizing this topic in the present day include the Australian-German company Quantum Brilliance – a company that has set itself the mission of making drug discovery with quantum technology not a dream, but a reality. Founded in 2019, the startup is developing diamond quantum accelerators that can model interactions between several molecules for drug discovery and development in silico.
In January 2021, Boehringer Ingelheim entered into cooperation with Google Quantum AI, to apply quantum methods to drug development and in silico modeling. A month later, the pharmaceutical giant Roche announced a deal with Cambridge Quantum Computing to accelerate the development of drugs for Alzheimer’s disease in the early stage.
Well, have fewer questions remained about modern possibilities in the field of pharmaceutical technologies? After the next post there should be practically none left. So, follow the news, there’s more to come!

